The SPARK study is evaluating an investigational drug that targets alpha-synuclein (α-syn), a molecule associated with Parkinson’s disease, to see if it may potentially help to slow or reduce progression in the earliest stages of the disease. If you have been diagnosed within the past three years, are between 40 and 80 years of age (inclusive), and have not received levodopa to manage symptoms, you may be eligible to participate.

A Clinical Research Study for Newly or Recently Diagnosed Patients

To see if you qualify, contact our study center:

Ray James, BS, RN
617-638-7745
rcjames@bu.edu

All eligible study participants will receive at no cost:

- Investigational drug (at some point during study participation)
- Study-related care, consultation, and visits
- Reimbursement for study-related expenses and travel assistance (if necessary)